테라퓨틱스엠디(TXMD) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

TXMD

TherapeuticsMD Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$2.07

+0.01 ▲ +0.49%

테라퓨틱스엠디(TXMD) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$24M

스몰캡

P/E

134.4

고평가 구간

배당수익률

없음

52주 위치

55%

저점 +109% · 고점 -30%

애널리스트

보유

Fundamental health

vs. Drug Manufacturers - Specialty & Generic

수익성

Top 5%

성장

Top 32%

밸류에이션

Top 39%

재무 안정

Top 47%

💰 Is this stock pricier than usual right now?

Compared to this company's own recent 1년 (not other companies).

Very cheap

Cheap

Typical

Pricey

🔥 Very pricey

Simply put — what you pay today to own $1 of this company's yearly earnings is 165원. Over the past 1년, it usually traded around 0원. One of the priciest stretches of the past 1년.

Pricy doesn't mean bad — it means expectations are already baked in.· based on 1.3 profitable years

Index ⓘ	-	P/E ⓘ	134.42	EPS (ttm) ⓘ	0.02	Insider Own ⓘ	6.87%	Shs Outstand ⓘ	11.6M	Perf Week ⓘ	-1.9%
Market Cap ⓘ	0.02B	Forward P/E ⓘ	-	EPS next Y ⓘ	-	Insider Trans ⓘ	-	Shs Float ⓘ	10.8M	Perf Month ⓘ	1.97%
Enterprise Value ⓘ	0.02B	PEG ⓘ	-	EPS next Q ⓘ	-	Inst Own ⓘ	33.97%	Short Float ⓘ	0.4%	Perf Quarter ⓘ	-5.48%
Income ⓘ	0.00B	P/S ⓘ	7.15	EPS this Y ⓘ	-	Inst Trans ⓘ	11.43%	Short Ratio ⓘ	1.1	Perf Half Y ⓘ	-20.69%
Sales ⓘ	0.00B	P/B ⓘ	0.89	EPS next 5Y ⓘ	-	ROA ⓘ	0.23%	Short Interest ⓘ	0.04M	Perf YTD ⓘ	26.99%
Book/sh ⓘ	2.33	P/C ⓘ	2.85	EPS past 3/5Y ⓘ	83.18% 72.84%	ROE ⓘ	0.32%	52W High ⓘ	-29.83% ($2.95)	Perf Year ⓘ	73.95%
Cash/sh ⓘ	0.73	P/FCF ⓘ	8.97	Sales past 3/5Y ⓘ	-64.91% -45.84%	ROIC ⓘ	0.56%	52W Low ⓘ	109.09% ($0.99)	Perf 3Y ⓘ	-47.99%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	108.52%	Gross Margin ⓘ	57.56%	Volatility(W/M) ⓘ	3.35% 5.48%	Perf 5Y ⓘ	-95.94%
Dividend TTM ⓘ	-	EV/Sales ⓘ	6.38	Sales Y/Y TTM ⓘ	82.13%	Oper. Margin ⓘ	-111.66%	ATR (14) ⓘ	0.1	Perf 10Y ⓘ	-99.47%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	2.63	EPS Q/Q ⓘ	114.51%	Profit Margin ⓘ	5.34%	RSI (14) ⓘ	52.27	Recom ⓘ	3
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	2.63	Sales Q/Q ⓘ	84.22%	SMA20 ⓘ	1.02% ($2.05)	Beta ⓘ	0.61	Target Price ⓘ	$5
Payout ⓘ	-	Debt/Eq ⓘ	0.22	Earnings ⓘ	2026/3/30	SMA50 ⓘ	0.97% ($2.05)	Rel Volume ⓘ	0.25	Prev Close ⓘ	$2.06
Employees ⓘ	1	LT Debt/Eq ⓘ	0.18	EPS/Sales Surpr. ⓘ	-	SMA200 ⓘ	6.45% ($1.94)	Avg Volume(3M) ⓘ	0.04M	Price ⓘ	$2.07
IPO ⓘ	2002/1/3	Option/Short ⓘ	Yes/Yes			Trades ⓘ	102	Volume ⓘ	9,854	Change ⓘ	0.49%

Quarterly earnings trend SEC filings · USD

23.12*

24.3

24.6

24.9

25.3

25.6

25.9

26.3

Revenue Net income 최근 분기: 매출 $1M (YoY +84%) · 순이익 $0M (YoY +115%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 TherapeuticsMD Inc (TXMD) Investment Analysis

What kind of company is TherapeuticsMD Inc?

테라퓨틱스엠디(TXMD) 방어주

Healthcare · Drug Manufacturers - Specialty & Generic

Small-Cap — Low Volume, High Volatility

👩‍⚕️ This is a U.S. royalty-based women's health company that licenses out the commercialization rights for its self-developed hormone therapy products—IMVEXXY and BIJUVA—and the contraceptive ring ANNOVERA to Mayne Pharma and other partners in exchange for royalties. With no in-house sales or R&D operations, its business model centers entirely on licensing and royalty income.

Learn more about TherapeuticsMD Inc →

Market Cap

$0.0B

Approx. KRW 0.0 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank5204

Employees1people

IPO2002/01/03

Current Price$2.07 ≈ 2,836원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 3월 30일 (월) · 장 마감 후

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-111.7%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

5.3%

✓ 우수

My positionTop 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 Median -38.2% · Top tier

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

57.6%

✓ 우수

My positionTop 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 Median 26.6% · Top 24%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

0.3%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -98.0% · Top tier

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

0.2%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -59.3% · Top tier

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

0.6%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -77.3% · Top tier

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.22

✓ Healthy debt

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 0.36

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

2.63

✓ 양호

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 2.47

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

2.63

✓ 양호

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 1.68

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$5.00

현재가 대비 +141.5%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth

Mid-range within the industry

Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+83.2%

우수

My positionTop 25%

Low range Average High range

방어주 초소형주 Median 30.0% · Top 11%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+72.8%

우수

My positionTop 5%

Low range Average High range

방어주 초소형주 Median 16.4% · Top tier

Past 5-Year Revenue

How much revenue grew over the past 5 years

-45.8%

매우 부진

My positionBottom 5%

Low range Average High range

방어주 초소형주 Median 2.1% · Bottom tier

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+84.2%

우수

My positionTop 25%

Low range Average High range

방어주 초소형주 Median -4.5% · Top 17%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -164%p below the market

TXMD -95.9% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-164.3%p

Significantly behind the market

vs Health Care (XLV)

-120.4%p

Significantly behind the sector average

1-year basis

vs S&P 500

+57.9%p

well ahead of the market

vs Health Care (XLV)

+54.2%p

well ahead of the sector average

Rank among peers

5-year return Upper-Mid (50%) Based on 28 peers

1-year return Top among peers Based on 36 peers

Current position within 52-week range

Low (-109.1%p) High (-29.8%p)

Current price is 109.1% above the 52-week low and 29.8% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-26.6%

Annualized volatility

55.6%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-27

Uptrend zone

Current price $2.07 above the midline ($2.05). Normal upward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-27

Neutral zone — weak trend

MACD -0.000 · Signal -0.006 · Hist 0.006. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-27

Bullish zone

RSI 52.3 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 76.2.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

Cheap on Vs. Cash Flow, Pricey on Vs. Earnings·Vs. Sales, In line with peers on Vs. Assets

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Pricey

🏢 Vs. Assets Mid-range

🧾 Vs. Sales Pricey

💧 Vs. Cash Flow Cheap

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

134.42x

✓ Very pricey

My positionBottom 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic median 20.36x · Bottom 8% — expensive within the industry

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

0.89x

✓ Fair

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 median 0.78x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

7.15x

✓ Pricey

My positionBottom 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 median 1.82x · Bottom 25% — expensive within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

8.97x

✓ Very cheap

My positionTop 25%

Low range Average High range

Drug Manufacturers - Specialty & Generic median 18.10x · Top 25% — relatively cheap within the industry

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$5.00 vs. current price +141.5%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic

Who owns it?

Ownership flow is positive

Institutional net buying +11.4% · Short interest light 0.4%

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

+11.4%

Institutions large net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 34.0%

Moderate institutional participation

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 6.9%

Meaningful insider stake

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 59.2%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

0.4%

Low — limited short-side pressure

Healthcare 초소형주 Median 3.9%

Past 90 days Little change

Short interest days to cover

1.1 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 11.6M주

Float (tradable shares) 10.8M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding TXMD

ETFs with the highest weightings · 3 total shown

DFAC

Dimensional U.S. Core Equity 2 ETF

0.00%

$47.5B

VTI

Vanguard Total Stock Market ETF

0.00%

$657.4B

VXF

Vanguard Extended Market Index ETF

0.00%

$30.4B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
TXMD This Stock	$24.0M	134.4 ▼	0.9 ▲	0.32% ▲	-	+0.5%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 테라퓨틱스엠디(TXMD)?

테라퓨틱스엠디(TXMD) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of TXMD?

The market cap of TXMD is approximately $24M, ranking 5,204 within its sector.

What is the P/E ratio of TXMD?

TXMD has a P/E ratio of approximately 134.4x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for TXMD?

TXMD has recorded a 52-week high of $2.95 and a low of $0.99.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.